The Effects of Topical Antiglaucoma Drugs as Monotherapy on the Ocular Surface: A Prospective Study

Table 4

The mean count of goblet cells in superior-central and inferior-nasal conjunctiva.

Goblet cell count	Beginning	3rd month	6th month	12th month	𝐹	𝑃
Group 1
Superior	93.4 ± 48.95	86.47 ± 44.14	86.93 ± 53.62	79.93 ± 42.75	5.68	0.002
Inferior	94.13 ± 48.67	87.27 ± 43.48	88.33 ± 54.6	81.47 ± 47.42	6.62	0.001
Group 2
Superior	110.07 ± 41.49	99.21 ± 35.55	83.79 ± 43.54	85 ± 41.95	11.12	0.001
Inferior	120.43 ± 39.75	116.36 ± 35.09	113.29 ± 39.44	115.93 ± 34.18	0.61	0.616
Group 3
Superior	128.57 ± 34.23	129.93 ± 27.59	136.71 ± 37.15	114.79 ± 24.27	2.21	0.103
Inferior	132.86 ± 25.77	131.64 ± 29.52	127.57 ± 35.44	113.5 ± 39.96	2.96	0.044
Group 4
Superior	124.5 ± 30.58	105.5 ± 45.07	115.71 ± 38.79	119 ± 29.95	2.13	0.112
Inferior	132.21 ± 46.09	129.5 ± 42.33	126.21 ± 45.24	133.14 ± 35.97	0.33	0.802
Group 5
Superior	132.86 ± 20.78	127.43 ± 19.57	125.5 ± 15.77	119.14 ± 15.04	4.36	0.01
Inferior	148.86 ± 19.71	140.14 ± 17.94	134.79 ± 19.97	128.14 ± 17.95	10.06	0.047
Group 6
Superior	119.93 ± 41.51	130.79 ± 40.93	127.21 ± 55.32	114.21 ± 40.28	1.56	0.216
Inferior	174.07 ± 105.51	144.29 ± 51.59	135.64 ± 58.39	129.57 ± 43.14	2.89	0.001
𝐹	2.17; 3.43	3.75; 4.32	3.81; 2.40	3.98; 3.75
𝑃	0.066; 0.07	0.004; 0.002	0.004; 0.044	0.003; 0.004